Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.310 +0.070 (+5.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 88,393
Open 1.270
Bid (Size) 1.310 (100)
Ask (Size) 1.320 (200)
Prev. Close 1.240
Today's Range 1.240 - 1.395
52wk Range 0.0661 - 3.250
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire

Performance

YTD
-34.2%
-34.2%
1 Month
+28.4%
+28.4%
3 Month
-51.3%
-51.3%
6 Month
+37.6%
+37.6%
1 Year
+35.1%
+35.1%

More News

Read More
News headline image
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-12-11: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Clearmind Medicine Announces 1-for-40 Reverse Share Split
From Clearmind Medicine Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?
Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
What exchange does Clearmind Medicine Inc. - Common Shares trade on?
Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
What is the current price of Clearmind Medicine Inc. - Common Shares?
The current price of Clearmind Medicine Inc. - Common Shares is 1.310
When was Clearmind Medicine Inc. - Common Shares last traded?
The last trade of Clearmind Medicine Inc. - Common Shares was at 04/08/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.